Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12563243 | 0.81 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL12604769 | 0.81 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL11536438 | 0.81 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL12869253 | 0.80 | TP53 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL12869250 | 0.80 | TP53 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL5511730 | 0.80 | TP53 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL13324761 | 0.76 | TP53 (0.35) | SLC7A5TP53 | |
| SCHEMBL25564622 | 0.74 | TP53 (0.39) | SLC7A5TP53 | |
| Cadaverine Tartrate SCHEMBL7319560 | 0.72 | TSHR (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL14670244 | 0.70 | ALDH1A1 (0.33) | SLC7A5ALDH1A1MAPTPTGS1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2327685-B1 | PROCESS FOR PRODUCTION OF ALPHA-TRIFLUOROMETHYL- BETA-SUBSTITUTED- BETA -AMINO ACID | CENTRAL GLASS CO LTD (JP) | 2015-10-14 | — | — | EP | disclosed |
| US-8524913-B2 | Process for production of α-trifluoromethyl-β-substituted-β-amino acid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524913-B2 | Process for production of α-trifluoromethyl-β-substituted-β-amino acid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110152536-A1 | Process for Production of Alpha-Trifluoromethyl-Beta-Substituted-Beta-Amino Acid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152536-A1 | Process for Production of Alpha-Trifluoromethyl-Beta-Substituted-Beta-Amino Acid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2327685-A1 | PROCESS FOR PRODUCTION OF -TRIFLUOROMETHYL- -SUBSTITUTED- -AMINO ACID | Central Glass Company, Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152536-A1 | Process for Production of Alpha-Trifluoromethyl-Beta-Substituted-Beta-Amino Acid | BCAT2, BCAT1, DAO | SLC7A5 605/4885SLC1A3 1024/4885SLC1A2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.